TY - JOUR AU - Ferrari, S. AU - Palmerini, E. PY - 2007 DA - 2007// TI - Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma JO - Curr Opin Oncol VL - 19 UR - https://doi.org/10.1097/CCO.0b013e328122d73f DO - 10.1097/CCO.0b013e328122d73f ID - Ferrari2007 ER - TY - JOUR AU - Bielack, S. S. AU - Kempf-Bielack, B. AU - Delling, G. PY - 2002 DA - 2002// TI - Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.20.3.776 DO - 10.1200/JCO.20.3.776 ID - Bielack2002 ER - TY - JOUR AU - Ferrari, S. AU - Briccoli, A. AU - Mercuri, M. PY - 2003 DA - 2003// TI - Pos t relapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.03.141 DO - 10.1200/JCO.2003.03.141 ID - Ferrari2003 ER - TY - JOUR PY - 2014 DA - 2014// TI - Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu256 DO - 10.1093/annonc/mdu256 ID - ref4 ER - TY - JOUR AU - Rosen, G. AU - Forscher, C. AU - Lowenbraun, S. PY - 1994 DA - 1994// TI - Synovial sarcoma. Uniform response of metastases to high dose ifosfamide JO - Cancer VL - 73 UR - https://doi.org/3.0.CO;2-S DO - 3.0.CO;2-S ID - Rosen1994 ER - TY - JOUR AU - Patel, S. R. AU - Vadhan-Raj, S. AU - Papadopolous, N. PY - 1997 DA - 1997// TI - High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose–response and schedule dependence JO - J Clin Oncol VL - 15 ID - Patel1997 ER - TY - JOUR AU - Duffaud, F. AU - Egerer, G. AU - Ferrari, S. PY - 2012 DA - 2012// TI - A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2011.12.015 DO - 10.1016/j.ejca.2011.12.015 ID - Duffaud2012 ER - TY - JOUR AU - Grignani, G. AU - Palmerini, E. AU - Dileo, P. PY - 2012 DA - 2012// TI - A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mdr151 DO - 10.1093/annonc/mdr151 ID - Grignani2012 ER - TY - JOUR AU - Grignani, G. AU - Palmerini, E. AU - Ferraresi, V. PY - 2015 DA - 2015// TI - Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71136-2 DO - 10.1016/S1470-2045(14)71136-2 ID - Grignani2015 ER - TY - JOUR AU - Pautier, P. AU - Floquet, A. AU - Penel, N. PY - 2012 DA - 2012// TI - Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study) JO - Oncologist VL - 17 UR - https://doi.org/10.1634/theoncologist.2011-0467 DO - 10.1634/theoncologist.2011-0467 ID - Pautier2012 ER - TY - JOUR AU - Maki, R. G. AU - Wathen, J. K. AU - Patel, S. R. PY - 2007 DA - 2007// TI - Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected] JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.10.4117 DO - 10.1200/JCO.2006.10.4117 ID - Maki2007 ER - TY - JOUR AU - Hensley, M. L. AU - Maki, R. AU - Venkatraman, E. PY - 2002 DA - 2002// TI - Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.11.050 DO - 10.1200/JCO.2002.11.050 ID - Hensley2002 ER - TY - JOUR AU - Merimsky, O. AU - Meller, I. AU - Kollender, Y. PY - 2000 DA - 2000// TI - Gemcitabine in bone sarcoma resistant to Doxorubicin-based chemotherapy JO - Sarcoma VL - 4 UR - https://doi.org/10.1155/S1357714X00000025 DO - 10.1155/S1357714X00000025 ID - Merimsky2000 ER - TY - JOUR AU - Navid, F. AU - Willert, J. R. AU - McCarville, M. B. PY - 2008 DA - 2008// TI - Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma JO - Cancer VL - 113 UR - https://doi.org/10.1002/cncr.23586 DO - 10.1002/cncr.23586 ID - Navid2008 ER - TY - JOUR AU - Fox, E. AU - Patel, S. AU - Wathen, J. K. PY - 2012 DA - 2012// TI - Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003 JO - Oncologist VL - 17 UR - https://doi.org/10.1634/theoncologist.2010-0265 DO - 10.1634/theoncologist.2010-0265 ID - Fox2012 ER - TY - JOUR AU - Gosiengfiao, Y. AU - Reichek, J. AU - Woodman, J. PY - 2012 DA - 2012// TI - Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital JO - J Pediatr Hematol Oncol VL - 34 UR - https://doi.org/10.1097/MPH.0b013e3182331ee8 DO - 10.1097/MPH.0b013e3182331ee8 ID - Gosiengfiao2012 ER - TY - JOUR AU - He, A. N. AU - Tang, L. N. AU - Shen, Z. PY - 2012 DA - 2012// TI - Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients JO - Jpn J Clin Oncol VL - 42 UR - https://doi.org/10.1093/jjco/hyr195 DO - 10.1093/jjco/hyr195 ID - He2012 ER - TY - JOUR AU - Song, B. S. AU - Seo, J. AU - Kim, D. H. PY - 2014 DA - 2014// TI - Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience JO - Pediatr Blood Cancer VL - 61 UR - https://doi.org/10.1002/pbc.25035 DO - 10.1002/pbc.25035 ID - Song2014 ER - TY - JOUR AU - Glabbeke, M. AU - Verweij, J. AU - Judson, I. PY - 2002 DA - 2002// TI - Progression-free rate as the principal end-point for phase II trials insoft-tissue sarcomas JO - Eur J Cancer VL - 38 UR - https://doi.org/10.1016/S0959-8049(01)00398-7 DO - 10.1016/S0959-8049(01)00398-7 ID - Glabbeke2002 ER - TY - JOUR AU - Harris, M. B. AU - Cantor, A. B. AU - Goorin, A. M. PY - 1995 DA - 1995// TI - Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a PediatricOncology Group study JO - Med Pediatr Oncol VL - 24 UR - https://doi.org/10.1002/mpo.2950240205 DO - 10.1002/mpo.2950240205 ID - Harris1995 ER - TY - STD TI - Lee SH, Chang MH, Baek KK, et al. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. Oncology. 2011;80(3-4):257-61. ID - ref21 ER - TY - JOUR AU - Berger, M. AU - Grignani, G. AU - Ferrari, S. PY - 2009 DA - 2009// TI - Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients JO - Cancer VL - 115 UR - https://doi.org/10.1002/cncr.24368 DO - 10.1002/cncr.24368 ID - Berger2009 ER - TY - JOUR AU - Rodríguez-Galindo, C. AU - Daw, N. C. AU - Kaste, S. C. PY - 2002 DA - 2002// TI - Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide JO - J Pediatr Hematol Oncol VL - 24 UR - https://doi.org/10.1097/00043426-200205000-00006 DO - 10.1097/00043426-200205000-00006 ID - Rodríguez-Galindo2002 ER - TY - JOUR AU - Berrak, S. G. AU - Pearson, M. AU - Berberoğlu, S. AU - Ilhan, I. E. AU - Jaffe, N. PY - 2005 DA - 2005// TI - High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicit JO - Pediatr Blood Cancer VL - 44 UR - https://doi.org/10.1002/pbc.20228 DO - 10.1002/pbc.20228 ID - Berrak2005 ER - TY - JOUR AU - Joerger, M. PY - 2012 DA - 2012// TI - Prevention and handling of acute allergic and infusion reactions in oncology JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds314 DO - 10.1093/annonc/mds314 ID - Joerger2012 ER - TY - JOUR AU - Benjamin, R. S. PY - 2015 DA - 2015// TI - Osteosarcoma: better treatment through better trial design JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71186-6 DO - 10.1016/S1470-2045(14)71186-6 ID - Benjamin2015 ER -